Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease. Rapamycin, already used in clinical settings, may be a potentially effective therapeutic agent for the treatment of AD.
No takes yet. Share an insight, caveat, or question.
Spilman et al. (2010) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: